{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:32Z","timestamp":1792783412913,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Guangdong Pharmaceutical Association Hospital Pharmacy Research Fund","award":["2024-0808-02"],"award-info":[{"award-number":["2024-0808-02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40261-025-01447-6","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T13:27:11Z","timestamp":1747229231000},"page":"295-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk of Ophthalmotoxicity Associated with Antibody-Drug Conjugates: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"45","author":[{"given":"Xin","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0870-382X","authenticated-orcid":false,"given":"Junyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"21","key":"1447_CR1","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1158\/1078-0432.Ccr-12-1803","volume":"18","author":"RA de Claro","year":"2012","unstructured":"de Claro RA, McGinn K, Kwitkowski V, et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18(21):5845\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-1803.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"1447_CR2","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1021\/jm500766w","volume":"57","author":"JM Lambert","year":"2014","unstructured":"Lambert JM, Chari RV. Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 2014;57(16):6949\u201364. https:\/\/doi.org\/10.1021\/jm500766w.","journal-title":"J Med Chem"},{"issue":"8","key":"1447_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, et al. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361. https:\/\/doi.org\/10.1038\/s41573-023-00709-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1447_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/jco.22.01643","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023;41(1):22\u201331. https:\/\/doi.org\/10.1200\/jco.22.01643.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1447_CR5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Moore KN, Betella I, et al. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111(6):538\u201349. https:\/\/doi.org\/10.1093\/jnci\/djz035.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1447_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1080\/13696998.2022.2041320","volume":"25","author":"D Zou","year":"2022","unstructured":"Zou D, Lee J, Kansal A, et al. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada. J Med Econ. 2022;25(1):324\u201333. https:\/\/doi.org\/10.1080\/13696998.2022.2041320.","journal-title":"J Med Econ"},{"issue":"7","key":"1447_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/coc.0000000000000816","volume":"44","author":"J Sussell","year":"2021","unstructured":"Sussell J, Singh Jhuti G, Antao V, et al. Cost-effectiveness analysis of ado-trastuzumab emtansine (T-DM1) for the adjuvant treatment of patients with residual invasive HER2+ early breast cancer in the United States. Am J Clin Oncol. 2021;44(7):340\u20139. https:\/\/doi.org\/10.1097\/coc.0000000000000816.","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"1447_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s40273-019-00779-4","volume":"37","author":"E Cox","year":"2019","unstructured":"Cox E, Wade R, Peron M, et al. The clinical and cost effectiveness of inotuzumab ozogamicin for the treatment of adult relapsed or refractory B-cell acute lymphoblastic leukaemia: an Evidence Review Group evaluation of a NICE single technology appraisal. Pharmacoeconomics. 2019;37(9):1081\u201391. https:\/\/doi.org\/10.1007\/s40273-019-00779-4.","journal-title":"Pharmacoeconomics"},{"issue":"21","key":"1447_CR9","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/cancers16213689","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Ayasun R, Rizzo A, et al. Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis. Cancers (Basel). 2024;16(21):3689. https:\/\/doi.org\/10.3390\/cancers16213689.","journal-title":"Cancers (Basel)."},{"issue":"10","key":"1447_CR10","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.3390\/cancers14102429","volume":"14","author":"A Di Federico","year":"2022","unstructured":"Di Federico A, Mosca M, Pagani R, et al. Immunotherapy in pancreatic cancer: why do we keep failing? A focus on tumor immune microenvironment, predictive biomarkers and treatment outcomes. Cancers (Basel). 2022;14(10):2429. https:\/\/doi.org\/10.3390\/cancers14102429.","journal-title":"Cancers (Basel)."},{"issue":"11","key":"1447_CR11","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3390\/jpm12111788","volume":"12","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Ricci AD, Brandi G. Trans-arterial chemoembolization plus systemic treatments for hepatocellular carcinoma: an update. J Pers Med. 2022;12(11):1788. https:\/\/doi.org\/10.3390\/jpm12111788.","journal-title":"J Pers Med."},{"issue":"18","key":"1447_CR12","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.2217\/fon-2021-1647","volume":"18","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Cusmai A, Acquafredda S, et al. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future Oncol. 2022;18(18):2301\u20139. https:\/\/doi.org\/10.2217\/fon-2021-1647.","journal-title":"Future Oncol"},{"issue":"12","key":"1447_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00520-023-08083-w","volume":"31","author":"DC Guven","year":"2023","unstructured":"Guven DC, Erul E, Kaygusuz Y, et al. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 2023;31(12):624. https:\/\/doi.org\/10.1007\/s00520-023-08083-w.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1447_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","volume":"183","author":"MD Hackshaw","year":"2020","unstructured":"Hackshaw MD, Danysh HE, Singh J, et al. Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;183(1):23\u201339. https:\/\/doi.org\/10.1007\/s10549-020-05754-8.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1447_CR15","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/jat.3582","volume":"38","author":"S Taplin","year":"2018","unstructured":"Taplin S, Vashisht K, Walles M, et al. Hepatotoxicity with antibody maytansinoid conjugates: a review of preclinical and clinical findings. J Appl Toxicol. 2018;38(5):600\u201315. https:\/\/doi.org\/10.1002\/jat.3582.","journal-title":"J Appl Toxicol"},{"issue":"5","key":"1447_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337. https:\/\/doi.org\/10.1038\/nrd.2016.268.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"1447_CR17","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1359::AID-CNCR1>3.0.Co;2-G","volume":"78","author":"T al-Tweigeri","year":"1996","unstructured":"al-Tweigeri T, Nabholtz JM, Mackey JR. Ocular toxicity and cancer chemotherapy: a review. Cancer. 1996;78(7):1359\u201373. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19961001)78:7%3c1359::AID-CNCR1%3e3.0.Co;2-G.","journal-title":"Cancer"},{"issue":"26","key":"1447_CR18","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/jco.2011.41.5851","volume":"30","author":"DJ Renouf","year":"2012","unstructured":"Renouf DJ, Velazquez-Martin JP, Simpson R, et al. Ocular toxicity of targeted therapies. J Clin Oncol. 2012;30(26):3277\u201386. https:\/\/doi.org\/10.1200\/jco.2011.41.5851.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1447_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1089\/jop.2023.0069","volume":"39","author":"M Jaffry","year":"2023","unstructured":"Jaffry M, Choudhry H, Aftab OM, et al. Antibody-drug conjugates and ocular toxicity. J Ocul Pharmacol Ther. 2023;39(10):675\u201391. https:\/\/doi.org\/10.1089\/jop.2023.0069.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"10","key":"1447_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, et al. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31(10):589\u2013604. https:\/\/doi.org\/10.1089\/jop.2015.0064.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"1447_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","volume":"36","author":"JC Masters","year":"2018","unstructured":"Masters JC, Nickens DJ, Xuan D, et al. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs. 2018;36(1):121\u201335. https:\/\/doi.org\/10.1007\/s10637-017-0520-6.","journal-title":"Invest New Drugs"},{"issue":"2","key":"1447_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","volume":"129","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu K, Wang K, et al. Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer. 2023;129(2):283\u201395. https:\/\/doi.org\/10.1002\/cncr.34507.","journal-title":"Cancer"},{"issue":"5","key":"1447_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/cai2.97","volume":"2","author":"J Li","year":"2023","unstructured":"Li J, Shen G, Liu Z, et al. Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer Innov. 2023;2(5):346\u201375. https:\/\/doi.org\/10.1002\/cai2.97.","journal-title":"Cancer Innov."},{"issue":"5","key":"1447_CR24","doi-asserted-by":"publisher","first-page":"pkad069","DOI":"10.1093\/jncics\/pkad069","volume":"7","author":"Y Suzuki","year":"2023","unstructured":"Suzuki Y, Zhou S, Ota Y, et al. Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis. JNCI Cancer Spectr. 2023;7(5):pkad069. https:\/\/doi.org\/10.1093\/jncics\/pkad069.","journal-title":"JNCI Cancer Spectr."},{"key":"1447_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"7","key":"1447_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7326\/m13-0480","volume":"160","author":"DM Hartung","year":"2014","unstructured":"Hartung DM, Zarin DA, Guise JM, et al. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. Ann Intern Med. 2014;160(7):477\u201383. https:\/\/doi.org\/10.7326\/m13-0480.","journal-title":"Ann Intern Med"},{"key":"1447_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"issue":"7650","key":"1447_CR28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"issue":"343","key":"1447_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002","volume":"22","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;22(343): d4002. https:\/\/doi.org\/10.1136\/bmj.d4002.","journal-title":"BMJ"},{"issue":"15","key":"1447_CR30","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","volume":"391","author":"AF Herrera","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma. N Engl J Med. 2024;391(15):1379\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2405888.","journal-title":"N Engl J Med"},{"issue":"6","key":"1447_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/s1470-2045(17)30313-3","volume":"18","author":"IE Krop","year":"2017","unstructured":"Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743\u201354. https:\/\/doi.org\/10.1016\/s1470-2045(17)30313-3.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1447_CR32","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/s1470-2045(17)30312-1","volume":"18","author":"V Di\u00e9ras","year":"2017","unstructured":"Di\u00e9ras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(17)30312-1.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1447_CR33","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/cncr.31249","volume":"124","author":"EJ Jabbour","year":"2018","unstructured":"Jabbour EJ, DeAngelo DJ, Stelljes M, et al. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018;124(8):1722\u201332. https:\/\/doi.org\/10.1002\/cncr.31249.","journal-title":"Cancer"},{"issue":"11","key":"1447_CR34","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","volume":"34","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg JE, Powles T, Sonpavde GP, et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 2023;34(11):1047\u201354. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.016.","journal-title":"Ann Oncol"},{"issue":"10","key":"1447_CR35","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"},{"issue":"16","key":"1447_CR36","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"issue":"10","key":"1447_CR37","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/s2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801\u201312. https:\/\/doi.org\/10.1016\/s2352-3026(23)00243-0.","journal-title":"Lancet Haematol."},{"issue":"5","key":"1447_CR38","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391(5):408\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403407.","journal-title":"N Engl J Med"},{"issue":"5","key":"1447_CR39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(5):393\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2405090.","journal-title":"N Engl J Med"},{"issue":"1","key":"1447_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Fujiwara K, et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med. 2024;391(1):44\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2313811.","journal-title":"N Engl J Med"},{"issue":"20","key":"1447_CR41","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1182\/blood-2010-09-309229","volume":"117","author":"HF Fernandez","year":"2011","unstructured":"Fernandez HF, Sun Z, Litzow MR, et al. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood. 2011;117(20):5306\u201313. https:\/\/doi.org\/10.1182\/blood-2010-09-309229.","journal-title":"Blood"},{"issue":"27","key":"1447_CR42","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/jco.2014.55.3628","volume":"32","author":"AS Gamis","year":"2014","unstructured":"Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021\u201332. https:\/\/doi.org\/10.1200\/jco.2014.55.3628.","journal-title":"J Clin Oncol"},{"issue":"10094","key":"1447_CR43","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/s0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(17)31266-7.","journal-title":"Lancet"},{"issue":"6","key":"1447_CR44","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/s2352-3026(21)00102-2","volume":"8","author":"DJ Straus","year":"2021","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e410\u201321. https:\/\/doi.org\/10.1016\/s2352-3026(21)00102-2.","journal-title":"Lancet Haematol."},{"issue":"10168","key":"1447_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(18)32984-2.","journal-title":"Lancet"},{"key":"1447_CR46","unstructured":"National Library of Medicine. Study of brentuximab vedotin combined with RCHOP or RCHP in front-line treatment of patients with diffuse large B-cell lymphoma (DLBCL). Available from: https:\/\/clinicaltrials.gov\/search?id=AREA[NCTId](NCT01925612). Accessed 17 Oct 2023."},{"issue":"26","key":"1447_CR47","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood.2020009806","volume":"137","author":"EJ Lowe","year":"2021","unstructured":"Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137(26):3595\u2013603. https:\/\/doi.org\/10.1182\/blood.2020009806.","journal-title":"Blood"},{"issue":"18","key":"1447_CR48","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","volume":"387","author":"SM Castellino","year":"2022","unstructured":"Castellino SM, Pei Q, Parsons SK, et al. Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin\u2019s lymphoma. N Engl J Med. 2022;387(18):1649\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2206660.","journal-title":"N Engl J Med"},{"issue":"21","key":"1447_CR49","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1200\/jco.20.03398","volume":"39","author":"SM Tolaney","year":"2021","unstructured":"Tolaney SM, Tayob N, Dang C, et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol. 2021;39(21):2375\u201385. https:\/\/doi.org\/10.1200\/jco.20.03398.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1447_CR50","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/jco.2012.44.9694","volume":"31","author":"SA Hurvitz","year":"2013","unstructured":"Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157\u201363. https:\/\/doi.org\/10.1200\/jco.2012.44.9694.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1447_CR51","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med"},{"issue":"5","key":"1447_CR52","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1200\/jco.21.00896","volume":"40","author":"IE Krop","year":"2022","unstructured":"Krop IE, Im SA, Barrios C, et al. Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2-positive early breast cancer: the phase III KAITLIN study. J Clin Oncol. 2022;40(5):438\u201348. https:\/\/doi.org\/10.1200\/jco.21.00896.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1447_CR53","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/jco.19.00882","volume":"37","author":"SA Hurvitz","year":"2019","unstructured":"Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study. J Clin Oncol. 2019;37(25):2206\u201316. https:\/\/doi.org\/10.1200\/jco.19.00882.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1447_CR54","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/s12885-019-5687-0","volume":"19","author":"EA Perez","year":"2019","unstructured":"Perez EA, de Haas SL, Eiermann W, et al. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine \u00b1 pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer. 2019;19(1):517. https:\/\/doi.org\/10.1186\/s12885-019-5687-0.","journal-title":"BMC Cancer"},{"issue":"2","key":"1447_CR55","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/jco.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155\u201365. https:\/\/doi.org\/10.1200\/jco.19.00172.","journal-title":"J Clin Oncol"},{"issue":"10411","key":"1447_CR56","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/s0140-6736(23)01245-x","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423\u201333. https:\/\/doi.org\/10.1016\/s0140-6736(23)01245-x.","journal-title":"Lancet"},{"issue":"24","key":"1447_CR57","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/jco.24.00733","volume":"42","author":"LG Paz-Ares","year":"2024","unstructured":"Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study. J Clin Oncol. 2024;42(24):2860\u201372. https:\/\/doi.org\/10.1200\/jco.24.00733.","journal-title":"J Clin Oncol"},{"issue":"10390","key":"1447_CR58","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/s0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, Hee Park Y, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10390):1773\u201385. https:\/\/doi.org\/10.1016\/s0140-6736(23)00725-0.","journal-title":"Lancet"},{"issue":"1","key":"1447_CR59","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"issue":"25","key":"1447_CR60","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2004413.","journal-title":"N Engl J Med"},{"issue":"2","key":"1447_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40135-024-00322-5","volume":"12","author":"ES Lindgren","year":"2024","unstructured":"Lindgren ES, Yan R, Cil O, et al. Incidence and mitigation of corneal pseudomicrocysts induced by antibody-drug conjugates (ADCs). Curr Ophthalmol Rep. 2024;12(2):13\u201322. https:\/\/doi.org\/10.1007\/s40135-024-00322-5.","journal-title":"Curr Ophthalmol Rep."},{"issue":"11","key":"1447_CR62","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1007\/s12094-023-03261-y","volume":"25","author":"S Dom\u00ednguez-Llamas","year":"2023","unstructured":"Dom\u00ednguez-Llamas S, Caro-Magdaleno M, Mataix-Albert B, et al. Adverse events of antibody-drug conjugates on the ocular surface in cancer therapy. Clin Transl Oncol. 2023;25(11):3086\u2013100. https:\/\/doi.org\/10.1007\/s12094-023-03261-y.","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"1447_CR63","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","volume":"9","author":"AV Farooq","year":"2020","unstructured":"Farooq AV, Degli Esposti S, Popat R, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9(4):889\u2013911. https:\/\/doi.org\/10.1007\/s40123-020-00280-8.","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"1447_CR64","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207\u201321. https:\/\/doi.org\/10.1016\/s1470-2045(19)30788-0.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1447_CR65","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/14740338.2023.2251380","volume":"22","author":"F Raheem","year":"2023","unstructured":"Raheem F, Alsuhebany N, Hickey Zacholski E, et al. Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies. Expert Opin Drug Saf. 2023;22(10):921\u20138. https:\/\/doi.org\/10.1080\/14740338.2023.2251380.","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"1447_CR66","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/0008-5472.Can-17-3202","volume":"78","author":"H Zhao","year":"2018","unstructured":"Zhao H, Atkinson J, Gulesserian S, et al. Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates. Cancer Res. 2018;78(8):2115\u201326. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-3202.","journal-title":"Cancer Res"},{"issue":"6","key":"1447_CR67","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1158\/1078-0432.Ccr-18-2474","volume":"25","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Birrer MJ, O\u2019Malley DM, et al. Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine. Clin Cancer Res. 2019;25(6):1727\u201336. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2474.","journal-title":"Clin Cancer Res"},{"key":"1447_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678634","volume":"11","author":"A Wahab","year":"2021","unstructured":"Wahab A, Rafae A, Mushtaq K, et al. Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front Oncol. 2021;11: 678634. https:\/\/doi.org\/10.3389\/fonc.2021.678634.","journal-title":"Front Oncol"},{"key":"1447_CR69","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2147\/imcrj.S324394","volume":"14","author":"A Thibodeau","year":"2021","unstructured":"Thibodeau A, Nallasamy N. Bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin. Int Med Case Rep J. 2021;14:707\u20139. https:\/\/doi.org\/10.2147\/imcrj.S324394.","journal-title":"Int Med Case Rep J."},{"issue":"6","key":"1447_CR70","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/icu.0000000000001063","volume":"35","author":"RF Marshall","year":"2024","unstructured":"Marshall RF, Xu H, Berkenstock M. Ocular toxicities associated with antibody drug conjugates. Curr Opin Ophthalmol. 2024;35(6):494\u20138. https:\/\/doi.org\/10.1097\/icu.0000000000001063.","journal-title":"Curr Opin Ophthalmol"},{"issue":"6","key":"1447_CR71","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32(6):757\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.017.","journal-title":"Ann Oncol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01447-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01447-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01447-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:02:49Z","timestamp":1749186169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01447-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1447"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01447-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"24 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by a grant from the Guangdong Pharmaceutical Association Hospital Pharmacy Research Fund [2024-0808-02].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Xin Feng, Xiaoxia Yu, Shan Yang, Guosen Yuan, Min Huang, Zhichao He, and Junyan Wu have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available from the corresponding author, Junyan Wu, upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors commented on previous version of the manuscript. All authors read and approved the final manuscript. JW and ZH were involved in the conceptualization; ZH, XF, and XY contributed to the methodology; ZH, XY, SY, and GY were involved in the formal analysis and investigation; XF, XY, SY, and MH contributed to the original draft preparation; and JW and ZH were involved in the review and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}